Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gosuranemab - Biogen

Next Previous
Drug Profile

Gosuranemab - Biogen

Alternative Names: Anti-eTau; Anti-etau humanised IGG4 monoclonal antibody - Biogen; Anti-tau-mAb; BIIB092; BMS-986168; IPN-007

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iPierian
  • Developer Biogen; Bristol-Myers Squibb; iPierian
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Cardiovascular disorders; Metabolic disorders; Neurodegenerative disorders; Progressive supranuclear palsy

Most Recent Events

  • 26 Jul 2021 Efficacy and adverse events data from a phase Ib trial in in Neurodegenerative disorders (Tauopathies) presented at the Alzheimer's Association International Conference 2021 (AAIC-2021)
  • 16 Jun 2021 Discontinued - Phase-II for Alzheimer's disease in USA, Sweden, Spain, Australia, Poland, Japan, Italy, France and Germany (IV) (NCT03352557)
  • 16 Jun 2021 Adverse events and efficacy data from a phase II trial for Alzheimer's disease released by Biogen
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top